\
&
Contact us
\
&
Contact us
This was 2 years ago
LocationOnline
ProgrammesEurope's Rail is organising the third edition of their annual Innovation Days online (7-9 December 2022).
During these Innovation Days, they will discuss the results from the projects of the previous programme, "shift2rail". Additionally, more insights will be given as to how rail is positioning itself within the future of mobility. Technical aspects will be discussed as well, including (but not limited to) traction systems, running gear, KPI models, smart metering, switches and crossings, booking and ticketing solutions, multimodal travel, artificial intelligence, blockchain, condition based maintenance, intelligent video gate and much more.
You can read more about this event on the official announcement. You can find the programme agenda here. You can join through Teams for any sessions you deem relevant through this programme agenda.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
